X4 Pharmaceuticals, Inc (XFOR): R&D Expense
$72.72M
Year ended 2025-12-31
$66.39M
Trailing 12 months to 2026-06-30
+6.0%
3-year compound annual growth
+11.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $72.72M | -10.9% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $81.64M | +13.4% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $72.02M | +17.9% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $61.06M | +20.6% | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | $50.65M | +20.8% | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | $41.93M | +39.0% | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | $30.16M | +48.3% | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | $20.35M | +19.2% | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | $17.07M | n/c | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $17.83M | n/a | 2019-03-11, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗